Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

A Study to Evaluate Ibuprofen (IBU) 62.5 mg and Acetaminophen (APAP) 125 mg/5 ml in an Oral Liquid Suspension Fixed-Dose Combination Product in Children Aged 6 to 11 Years

← catalyst calendar

NCT07632274 · readout ≤ 42 d

Sponsored by HALEON (industry) · HLN — their whole pipeline →.

Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Na · None · Other
Enrollment
12estimated
Sites
1
Country
United States

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis
DateFiledBasisWhat it is
Start2026-06-19actualWhen the study began enrolling
Primary completionSep 2026estimatedThe date the last participant is measured for the primary outcome — the readout window
Study completionSep 2026estimatedThe whole study's end, after follow-up
First posted2026-06-08actualWhen this record first appeared on the registry
Results postedWhen the sponsor posted results to the registry
Record updated2026-06-30actualThe sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

  • Pain

Intervention

  • Drug: Test Product

Primary outcomes

what the primary-completion date above is the date OF
Area Under the Plasma Concentration Versus (Vs.) Time Curve Calculated from Time 0 to the Last Measurable Sampling Time Point (AUC0-t) for Ibuprofen and Acetaminophen
measured Pre-dose (within 1 hour prior to dosing) and at 5, 15, 30 minutes and 1 ,1.25, 1.5, 2, 4, 6, 9, 12 hours post dose on Day 1
Area Under the Plasma Concentration Vs. Time Curve Calculated from Time 0 To Infinity (AUC0-inf) for Ibuprofen and Acetaminophen
measured Pre-dose (within 1 hour prior to dosing) and at 5, 15, 30 minutes and 1, 1.25, 1.5, 2, 4, 6, 9, 12 hours post dose on Day 1
Peak or Maximum Observed Plasma Concentration (Cmax) for Ibuprofen and Acetaminophen
measured Pre-dose (within 1 hour prior to dosing) and at 5, 15, 30 minutes and 1, 1.25, 1.5, 2, 4, 6, 9, 12 hours post dose on Day 1
Time to Reach Maximum Plasma Concentration (Tmax) for Ibuprofen and Acetaminophen
measured Pre-dose (within 1 hour prior to dosing) and at 5, 15, 30 minutes and 1, 1.25, 1.5, 2, 4, 6, 9, 12 hours post dose on Day 1
Apparent Terminal Elimination Rate Constant (λz) for Ibuprofen and Acetaminophen
measured Pre-dose (within 1 hour prior to dosing) and at 5, 15, 30 minutes and 1, 1.25, 1.5, 2, 4, 6, 9, 12 hours post dose on Day 1
Terminal Half-Life (t1/2) for Ibuprofen and Acetaminophen
measured Pre-dose (within 1 hour prior to dosing) and at 5, 15, 30 minutes and 1, 1.25, 1.5, 2, 4, 6, 9, 12 hours post dose on Day 1
Apparent Volume of Distribution (Vz/F) for Ibuprofen and Acetaminophen
measured Pre-dose (within 1 hour prior to dosing) and at 5, 15, 30 minutes and 1, 1.25, 1.5, 2, 4, 6, 9, 12 hours post dose on Day 1
Apparent Total Clearance (Cl/F) for Ibuprofen and Acetaminophen
measured Pre-dose (within 1 hour prior to dosing) and at 5, 15, 30 minutes and 1, 1.25, 1.5, 2, 4, 6, 9, 12 hours post dose on Day 1
Apparent Volume of Distribution, Adjusted for Body Size (Vz/F/lbs) for Ibuprofen and Acetaminophen
measured Pre-dose (within 1 hour prior to dosing) and at 5, 15, 30 minutes and 1, 1.25, 1.5, 2, 4, 6, 9, 12 hours post dose on Day 1
Apparent Total Clearance, Adjusted for Body Size (Cl/F/lbs) for Ibuprofen and Acetaminophen
measured Pre-dose (within 1 hour prior to dosing) and at 5, 15, 30 minutes and 1, 1.25, 1.5, 2, 4, 6, 9, 12 hours post dose on Day 1

Permalink · HLN's whole pipeline · Catalyst calendar · Every registered study · What changed